Difference of Anxiety Subscale and Depression Score in Methamphetamine Abuse Prior and after Abstinence Over the Course of Three Weeks in Rehabilitation Center of Medan Plus

Yusuf Wibisono; Vita Camellia; Bahagia Loebis

doi:10.3889/oamjms.2022.9250

Authors

Yusuf Wibisono Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Vita Camellia Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-9749-6932
Bahagia Loebis Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9250

Keywords:

Abstinence, Methamphetamine, Hospital anxiety, Depression scale

Abstract

BACKGROUND: Clinical effect of amphetamine is related to the release of central monoamine in such a long period of time which leads to enhanced stimulation of sympathetic nervous system. Abstinence is defined as a period of restraint in which no substance is used. Anxiety and depression are most common psychiatry problem related to methamphetamine usage that has to be addressed in rehabilitation effort of methamphetamine abuse.

AIM: This study is to investigate the difference of anxiety subscale and depression (hospital anxiety and depression scale [HADS]) in methamphetamine abuse prior and after abstinence over the course of 3 weeks in rehabilitation center of Medan Plus.

METHODS: This quasi-experimental study was conducted with pre- and post-test design. Sample used in this research was generated through consecutive sampling, part of non-probability sampling, in which 30 subjects that are individuals with methamphetamine abuse were recruited in Rehabilitation Centre of Medan Plus, North Sumatera. Measurement was conducted to assist the effect of 3 weeks abstinence on HADS core. In the other hand, assessment smoking and substance involvement screening test was also used to investigate the length of substance usage.

RESULTS: Our study found a significant difference between anxiety and depression symptoms score prior and after 3 weeks abstinence in methamphetamine user (p < 0.001).

CONCLUSION: Following abstinence, several clinical symptoms were seen to be resolved or decreased within the first couple of weeks, including symptoms of anxiety and depression.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Díaz JE, Gaino LV, de Souza J. Clinical and socio-demographic characteristics of patients at a rehabilitation center for chemical dependency. Rev Gaucha Enferm. 2016;37(2):e57037. https://doi.org/10.1590-1447.2016.02.57037 PMid:27410673 DOI: https://doi.org/10.1590/1983-1447.2016.02.57037

Gyawali B, Choulagai BP, Paneru DP, Ahmad M, Leppin A, Kallestrup P. Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: A cross sectional study. BMC Psychiatry. 2016;16(1):314. http://dx.doi.org/10.1186/s12888-016-1003-6 PMid:27609330 DOI: https://doi.org/10.1186/s12888-016-1003-6

Bagheri M, Mokri A, Khosravi A, Kabir K. Effect of abstinence on depression, anxiety, and quality of life in chronic methamphetamine users in a therapeutic community. Int J High Risk Behav Addict. 2015;4(3):e23903. https://doi.org/10.5812/ijhrba.23903 PMid:26495258 DOI: https://doi.org/10.5812/ijhrba.23903

Seyed RR, Richard AR. Current research on methampetamine: Epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addict Health. 2014;6(3-4):147-54. PMid:25984282

Sadock BJ, Sadock VA, Ruis P. Substance use and addictive disorders. In: Kaplan and Sadock’s Synopsis of Psychiatry Behavioral Science/Clinical Psychiatry. 11th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2015. p. 1444-64.

Cuneyt E, Muge B. Update on metamphetamine: An old problem that we have recently encountered. Dusunen Adam J Psychiatry Neurol Sci. 2018;31:H0. https//doi.org/10.5350/DAJPN201831101001 DOI: https://doi.org/10.5350/DAJPN20183101001

David JH, Sharon LS, Jane G, David JN. Amphetamin-past and present a pharmacological and clinical perspective. J Psychopharmacol. 2014;27:480-94.

Rawson RA, Rachel G, Walter L. Metamphetamine abuse and dependence: An update. Direct Psychiatry. 2006;26(3):221-36.

Rocco AI, Roger DW. Stimuland related disorders. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 10th ed. Vol. 1. Philadelphia, PA: Lippincott Williams and Wilkins; 2017. p. 3297-26.

Kementerian Kesehatan Republik Indonesia. Pusat Data dan Informasi; 2014.